ReviewMolecular biology reports2025
Role of the renin-angiotensin pathway in epilepsy: a strategy for its management by drug repurposing.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Blood-Brain Barrier Disruption in Epilepsy: Mechanisms and Consequences.Neurology international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a neurological disorder characterised by aberrant synchronised neuronal activity in the brain and affects millions of people globally. The renin-angiotensin system (RAS) has been implicated in epilepsy pathophysiology, with angiotensin receptors playing pivotal role in seizure modulation and neuroprotection. This review explores the angiotensin-epilepsy axis, and elaborates upon the role of angiotensin receptors (AT-1, AT-2, AT-4, and Mas) in the CNS. AT-1 receptor stimulation is related to neuroinflammation, oxidative stress, and propagation of seizures, whereas their blockade by angiotensin receptor blockers (ARBs) demonstrated anticonvulsant and neuroprotective effects in preclinical model. AT-2 receptor activation down-regulates pro-inflammatory cytokines & protects the blood-brain barrier and induces neuronal survival and differentiation. They also interact with the AT-4 receptor identified as insulin-regulated amino peptidase (IRAP), a receptor that is implicated in its neuroinflammatory modulation, oxidative stress, and excitotoxicity. Against this background, the Mas receptor was recognized as the receptor for angiotensin-(1-7), leading to vasodilator, anti-inflammatory and anti-oxidant effects that oppose angiotensin II actions. This intricate interplay between these receptors and ligands accompanies the dynamic regulation of neurotransmitters, neuroinflammation, and neuroprotection in epileptic seizures. The role of the RAS in epilepsy may present new therapeutic targets in addressing this devastating disorder, especially in patients with coexisting cardiovascular illnesses.
Indexed as
Identifiers
40637915What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.